A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers.
about
A Phase IC Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Cognitive Outcomes of BI 409306 in Patients with Mild-to-Moderate Schizophrenia.Identification of new PDE9A isoforms and how their expression and subcellular compartmentalization in the brain change across the life span.Alzheimer's disease drug development pipeline: 2018.Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function
P2860
A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
A phase I, randomized, proof-o ...... 06 in healthy male volunteers.
@en
A phase I, randomized, proof-o ...... 06 in healthy male volunteers.
@nl
type
label
A phase I, randomized, proof-o ...... 06 in healthy male volunteers.
@en
A phase I, randomized, proof-o ...... 06 in healthy male volunteers.
@nl
prefLabel
A phase I, randomized, proof-o ...... 06 in healthy male volunteers.
@en
A phase I, randomized, proof-o ...... 06 in healthy male volunteers.
@nl
P2093
P2860
P356
P1476
A phase I, randomized, proof-o ...... 06 in healthy male volunteers.
@en
P2093
Chantaratsamon Dansirikul
Frank Runge
Heike Zimdahl-Gelling
Katja Boland
Lien Gheyle
Michael Sand
Solen Pichereau
Viktoria Moschetti
P2860
P356
10.1002/HUP.2569
P577
2017-01-01T00:00:00Z